These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 31521851)

  • 1. HPV vaccination: Are we overlooking additional opportunities to control HPV infection and transmission?
    Vorsters A; Van Damme P; Bosch FX
    Int J Infect Dis; 2019 Nov; 88():110-112. PubMed ID: 31521851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human papillomavirus vaccination induces neutralising antibodies in oral mucosal fluids.
    Handisurya A; Schellenbacher C; Haitel A; Senger T; Kirnbauer R
    Br J Cancer; 2016 Feb; 114(4):409-16. PubMed ID: 26867163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characteristics of HPV-specific antibody responses induced by infection and vaccination: cross-reactivity, neutralizing activity, avidity and IgG subclasses.
    Scherpenisse M; Schepp RM; Mollers M; Meijer CJ; Berbers GA; van der Klis FR
    PLoS One; 2013; 8(9):e74797. PubMed ID: 24058629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.
    Boxus M; Fochesato M; Miseur A; Mertens E; Dendouga N; Brendle S; Balogh KK; Christensen ND; Giannini SL
    J Virol; 2016 Jul; 90(14):6314-25. PubMed ID: 27147749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Developments in L2-based human papillomavirus (HPV) vaccines.
    Schellenbacher C; Roden RBS; Kirnbauer R
    Virus Res; 2017 Mar; 231():166-175. PubMed ID: 27889616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infection and vaccine-induced HPV-specific antibodies in cervicovaginal secretions. A review of the literature.
    Pattyn J; Van Keer S; Tjalma W; Matheeussen V; Van Damme P; Vorsters A
    Papillomavirus Res; 2019 Dec; 8():100185. PubMed ID: 31494291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review: current knowledge on the role of HPV antibodies after natural infection and vaccination: implications for monitoring an HPV vaccination programme.
    Mollers M; Vossen JM; Scherpenisse M; van der Klis FR; Meijer CJ; de Melker HE
    J Med Virol; 2013 Aug; 85(8):1379-85. PubMed ID: 23722396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccination with human papillomavirus pseudovirus-encapsidated plasmids targeted to skin using microneedles.
    Kines RC; Zarnitsyn V; Johnson TR; Pang YY; Corbett KS; Nicewonger JD; Gangopadhyay A; Chen M; Liu J; Prausnitz MR; Schiller JT; Graham BS
    PLoS One; 2015; 10(3):e0120797. PubMed ID: 25785935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Potential Benefits of HPV Vaccination in Previously Infected Women.
    Schiller JT
    EBioMedicine; 2016 Aug; 10():5-6. PubMed ID: 27515688
    [No Abstract]   [Full Text] [Related]  

  • 10. Sensitivity of Human Papillomavirus (HPV) Lineage and Sublineage Variant Pseudoviruses to Neutralization by Nonavalent Vaccine Antibodies.
    Godi A; Kemp TJ; Pinto LA; Beddows S
    J Infect Dis; 2019 Nov; 220(12):1940-1945. PubMed ID: 31412122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. N-terminal truncations on L1 proteins of human papillomaviruses promote their soluble expression in Escherichia coli and self-assembly in vitro.
    Wei M; Wang D; Li Z; Song S; Kong X; Mo X; Yang Y; He M; Li Z; Huang B; Lin Z; Pan H; Zheng Q; Yu H; Gu Y; Zhang J; Li S; Xia N
    Emerg Microbes Infect; 2018 Sep; 7(1):160. PubMed ID: 30254257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years.
    Einstein MH; Baron M; Levin MJ; Chatterjee A; Edwards RP; Zepp F; Carletti I; Dessy FJ; Trofa AF; Schuind A; Dubin G;
    Hum Vaccin; 2009 Oct; 5(10):705-19. PubMed ID: 19684472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccines for the prevention of human papillomavirus and associated gynecologic diseases: a review.
    Ault KA
    Obstet Gynecol Surv; 2006 Jun; 61(6 Suppl 1):S26-31. PubMed ID: 16729901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipidated L2 epitope repeats fused with a single-chain antibody fragment targeting human FcγRI elicited cross-neutralizing antibodies against a broad spectrum of human papillomavirus types.
    Zhang T; Liu H; Chen X; Wang Z; Wang S; Qu C; Zhang J; Xu X
    Vaccine; 2016 Nov; 34(46):5531-5539. PubMed ID: 27729176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human papillomavirus vaccines--immune responses.
    Stanley M; Pinto LA; Trimble C
    Vaccine; 2012 Nov; 30 Suppl 5():F83-7. PubMed ID: 23199968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibodies from women immunized with Gardasil cross-neutralize HPV 45 pseudovirions.
    Smith JF; Brownlow M; Brown M; Kowalski R; Esser MT; Ruiz W; Barr E; Brown DR; Bryan JT
    Hum Vaccin; 2007; 3(4):109-15. PubMed ID: 17611417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mucosal vaccination with a recombinant Salmonella typhimurium expressing human papillomavirus type 16 (HPV16) L1 virus-like particles (VLPs) or HPV16 VLPs purified from insect cells inhibits the growth of HPV16-expressing tumor cells in mice.
    Revaz V; Benyacoub J; Kast WM; Schiller JT; De Grandi P; Nardelli-Haefliger D
    Virology; 2001 Jan; 279(1):354-60. PubMed ID: 11145916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunogenicity of co-administered quadrivalent human papillomavirus (HPV)-6/11/16/18 L1 virus-like particle (VLP) and hepatitis B (HBV) vaccines.
    Wheeler CM; Bautista OM; Tomassini JE; Nelson M; Sattler CA; Barr E;
    Vaccine; 2008 Jan; 26(5):686-96. PubMed ID: 18164106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Single Human Papillomavirus Vaccine Dose Improves B Cell Memory in Previously Infected Subjects.
    Scherer EM; Smith RA; Gallego DF; Carter JJ; Wipf GC; Hoyos M; Stern M; Thurston T; Trinklein ND; Wald A; Galloway DA
    EBioMedicine; 2016 Aug; 10():55-64. PubMed ID: 27423190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: a partially-blind randomised placebo-controlled study.
    Denny L; Hendricks B; Gordon C; Thomas F; Hezareh M; Dobbelaere K; Durand C; Hervé C; Descamps D
    Vaccine; 2013 Nov; 31(48):5745-53. PubMed ID: 24091311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.